HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model.

AbstractBACKGROUND AND PURPOSE:
Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death, often induced by cigarette smoking (CS). It is characterized by pulmonary inflammation and fibrosis that impairs lung function. Existing treatments aim to control symptoms but have low efficacy, and there are no broadly effective treatments. A new potential target is the ectoenzyme, semicarbazide-sensitive mono-amine oxidase (SSAO; also known as vascular adhesion protein-1). SSAO is elevated in smokers' serum and is a pro-inflammatory enzyme facilitating adhesion and transmigration of leukocytes from the vasculature to sites of inflammation.
EXPERIMENTAL APPROACH:
PXS-4728A was developed as a low MW inhibitor of SSAO. A model of COPD induced by CS in mice reproduces key aspects of human COPD, including chronic airway inflammation, fibrosis and impaired lung function. This model was used to assess suppression of SSAO activity and amelioration of inflammation and other characteristic features of COPD.
KEY RESULTS:
Treatment with PXS-4728A completely inhibited lung and systemic SSAO activity induced by acute and chronic CS-exposure. Daily oral treatment inhibited airway inflammation (immune cell influx and inflammatory factors) induced by acute CS-exposure. Therapeutic treatment during chronic CS-exposure, when the key features of experimental COPD develop and progress, substantially suppressed inflammatory cell influx and fibrosis in the airways and improved lung function.
CONCLUSIONS AND IMPLICATIONS:
Treatment with a low MW inhibitor of SSAO, PXS-4728A, suppressed airway inflammation and fibrosis and improved lung function in experimental COPD, demonstrating the therapeutic potential of PXS-4728A for this debilitating disease.
AuthorsA G Jarnicki, H Schilter, G Liu, K Wheeldon, A-T Essilfie, J S Foot, T T Yow, W Jarolimek, P M Hansbro
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 173 Issue 22 Pg. 3161-3175 (11 2016) ISSN: 1476-5381 [Electronic] England
PMID27495192 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2016 The British Pharmacological Society.
Chemical References
  • Benzamides
  • Enzyme Inhibitors
  • PXS-4728A
  • Allylamine
  • Amine Oxidase (Copper-Containing)
Topics
  • Allylamine (analogs & derivatives, pharmacology)
  • Amine Oxidase (Copper-Containing) (antagonists & inhibitors, metabolism)
  • Animals
  • Benzamides (pharmacology)
  • Disease Models, Animal
  • Enzyme Inhibitors (pharmacology)
  • Female
  • Mice
  • Mice, Inbred C57BL
  • Pulmonary Disease, Chronic Obstructive (drug therapy, enzymology)
  • Smoking

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: